Company intelligence
IQ Consortium
International Consortium for Innovation & Quality in Pharmaceutical Development
About IQ Consortium
The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) is a technically-focused organization of pharmaceutical and biotechnology companies with a mission of advancing science-based and scientifically-driven standards and regulations for pharmaceutical and biotechnology products worldwide. IQ provides a sustained forum for the exchange of ideas within and across technical disciplines in these industries. The Consortium is leading initiatives in the areas of chemistry, manufacturing and control; preclinical safety; drug metabolism; clinical pharmacology; quality; and the reduction, refinement, and replacement of animal testing. As part of these initiatives, which are managed by Leadership Groups and Working Groups, members lead and participate in collaborative research, industry surveys and benchmarking exercises. IQ is also partnering with governmental bodies, other trade groups, and academic researchers. Through publications, scientific conferences, workshops and roundtables, the Consortium shares the results of its work and facilitates constructive scientific exchange.
Verified activity
Signals from IQ Consortium
2 published signals
Presence & Recognition
IQ Consortium is hosting an IQ Webinar titled Breaking the 1% unbundling: Plasma protein binding of high-level bound compounds on October 15, 2026, featuring Faraz Kazmi and J. Cory Kalvass.
Reported by IQ Consortium
Research & Knowledge
IQ Consortium published a new paper presenting findings from a collaboration involving 11 pharmaceutical companies demonstrating plasma protein binding for highly bound compounds can be measured accurately and reproducibly well below the historical 1% unbound fraction cutoff with values as low as ~0.003%
Reported by IQ Consortium